Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 597Stomach Neoplasms 72Neoplasm Metastasis 56Neoplasms 35HER2-positive Breast Cancer 30Breast Neoplasms, Male 30Colorectal Neoplasms 28Brain Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Inflammatory Breast Neoplasms 20Esophageal Neoplasms 20Pancreatic Neoplasms 13Triple Negative Breast Neoplasms 12Lung Neoplasms 11Endometrial Neoplasms 11Ovarian Neoplasms 10Colonic Neoplasms 10Urinary Bladder Neoplasms 9Rectal Neoplasms 9Prostatic Neoplasms 9Adenocarcinoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Breast Diseases 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6Pathologic Complete Response 6

Interventions

Paclitaxel 24Hyperthermic Intraperitoneal Chemotherapy 24Cisplatin 22Oxaliplatin 17Carboplatin 17Fluorouracil 13Cytoreduction Surgical Procedures 13Bevacizumab 10Mitomycin 9Leucovorin 8Doxorubicin 8Docetaxel 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Blood Specimen Collection 4Albumin-Bound Paclitaxel 4sodium thiosulfate 3liposomal doxorubicin 3catumaxomab 3Taxes 3Neoadjuvant Therapy 3Laparoscopy 3Drug Therapy 3tremelimumab 2relacorilant 2pembrolizumab 2olaparib 2nintedanib 2epothilone B 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Peritoneal Neoplasms × Trastuzumab × Clear all
NCT01384253 2016-09-30

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Orano Med LLC

Phase 1 Completed
18 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡